作者
Michael J Joyner, Katelyn A Bruno, Stephen A Klassen, Katie L Kunze, Patrick W Johnson, Elizabeth R Lesser, Chad C Wiggins, Jonathon W Senefeld, Allan M Klompas, David O Hodge, John RA Shepherd, Robert F Rea, Emily R Whelan, Andrew J Clayburn, Matthew R Spiegel, Sarah E Baker, Kathryn F Larson, Juan G Ripoll, Kylie J Andersen, Matthew R Buras, Matthew NP Vogt, Vitaly Herasevich, Joshua J Dennis, Riley J Regimbal, Philippe R Bauer, Janis E Blair, Camille M van Buskirk, Jeffrey L Winters, James R Stubbs, Noud van Helmond, Brian P Butterfield, Matthew A Sexton, Juan C Diaz Soto, Nigel S Paneth, Nicole C Verdun, Peter Marks, Arturo Casadevall, DeLisa Fairweather, Rickey E Carter, R Scott Wright
发表日期
2020/9/1
期刊
Mayo Clinic Proceedings
卷号
95
期号
9
页码范围
1888-1897
出版商
Elsevier
简介
Objective
To provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated safety in 5000 hospitalized patients.
Patients and Methods
From April 3 to June 2, 2020, the US Food and Drug Administration Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma.
Results
The incidence of all serious adverse events was low; these included transfusion reactions (n=78; <1%), thromboembolic or thrombotic events (n=113; <1%), and cardiac events (n=677, ~3%). Notably, the vast majority of the thromboembolic or thrombotic events (n=75) and cardiac events (n=597) were judged to be unrelated to the plasma transfusion per se. The 7-day mortality rate was 13.0% (12.5%, 13.4%), and was higher among more …
学术搜索中的文章
MJ Joyner, KA Bruno, SA Klassen, KL Kunze… - Mayo Clinic Proceedings, 2020